Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2021 Jan 22;16(1):e0245944. doi: 10.1371/journal.pone.0245944

The prion protein is not required for peripheral nerve de- and remyelination after crush injury

Anna Henzi 1, Adriano Aguzzi 1,*
Editor: Simone Di Giovanni2
PMCID: PMC7822300  PMID: 33481951

Abstract

The cellular prion protein (PrP) is essential to the long-term maintenance of myelin sheaths in peripheral nerves. PrP activates the adhesion G-protein coupled receptor Adgrg6 on Schwann cells and initiates a pro-myelination cascade of molecular signals. Because Adgrg6 is crucial for peripheral myelin development and regeneration after nerve injury, we investigated the role of PrP in peripheral nerve repair. We performed experimental sciatic nerve crush injuries in co-isogenic wild-type and PrP-deficient mice, and examined peripheral nerve repair processes. Generation of repair Schwann cells, macrophage recruitment and remyelination were similar in PrP-deficient and wild-type mice. We conclude that PrP is dispensable for sciatic nerve de- and remyelination after crush injury. Adgrg6 may sustain its function in peripheral nerve repair independently of its activation by PrP.

Introduction

Schwann cells, the glial cells of the peripheral nervous system (PNS) interact with axons and the extracellular matrix during development, maintenance and repair of peripheral nerves [1, 2]. In response to injury, Schwann cells exhibit a remarkable plasticity, which is central to the capacity for regeneration in the PNS [3]. The study of repair processes after experimental nerve cut or crush injuries in transgenic animals has unraveled many of the molecular mechanisms and signaling pathways driving Schwann cell plasticity [4, 5]. After injury, Schwann cells undergo reprogramming to become repair Schwann cells. While repair Schwann cells reactivate some developmental signaling pathways, they also acquire a set of unique features which are not found in developing Schwann cells [69]. Signaling of the adhesion G-protein coupled receptor Adgrg6 (formerly called Gpr126) was first described to initiate developmental myelination in zebrafish [10] and mice [11]. Later, a contribution of Adgrg6 to macrophage recruitment and remyelination after nerve crush injury was demonstrated [12], indicating that Adgrg6 is also involved in PNS repair. Furthermore, Adgrg6 is required for responses of terminal Schwann cells and regeneration of neuromuscular junctions [13], which is crucial for the restoration of function after peripheral nerve injury. Finally, ageing conditional Adgrg6 knockout mice showed signs of hindlimb denervation [13], suggesting a role of Adgrg6 signaling in maintenance of peripheral myelin. This notion is supported by the development of a progressive demyelinating neuropathy of the PNS in mice devoid of the cellular prion protein (PrP), an agonist of Adgrg6 [14, 15]. PrP is a glycophosphoinositol-anchored glycoprotein highly expressed in the nervous system [16] and mainly known for its role in prion diseases [17, 18]. The development of a chronic peripheral demyelinating neuropathy in PrP knockout mice has led to the identification of cellular PrP as necessary for myelin maintenance [15, 19]. Characterization of cell type-specific Prnp knockout mice revealed that PrP expressed by neurons but not by Schwann cells is required for peripheral myelin maintenance [15]. Neuronal PrP acts through Adgrg6 expressed on Schwann cells to activate pro-myelination signaling pathways [14]. While many phenotypes described in early generations of Prnp knockout mice have later been assigned to genetic confounders, the role of PrP in myelin maintenance has been confirmed in strictly co-isogenic C57BL/6J-Prnp knockout mice (PrnpZH3/ZH3) [20, 21].

The findings that PrP is an agonist of Adgrg6 and that Adgrg6 is involved in PNS repair raise the question whether PrP may also play a role in PNS repair. Here, we hypothesized that PrP may represent one of the ligands required to activate Adgrg6 after nerve injury. If so, PrP-deficient mice might develop similar defects in nerve regeneration as were reported in Adgrg6 knockout mice. While neuronal PrP expression is sufficient to support myelin maintenance, PrP from other cellular sources could contribute to remyelination and repair after injury. Therefore, we used PrnpZH3/ZH3 mice with global constitutive knockout of PrP for the experiments. To address our hypothesis, we performed nerve crush injuries in female PrnpZH3/ZH3 mice and compared the morphological and molecular stages of repair to wild type (WT) mice. Specifically, we assessed generation of repair Schwann cells, demyelination, recruitment of inflammatory cells and remyelination.

Contrary to our expectations, we detected no differences between PrnpZH3/ZH3 and WT mice in any of these processes. These findings suggest that PrP might be dispensable for peripheral nerve repair.

Material and methods

Mice

Breeding and maintenance of mice was performed in laboratory animal facilities (optimal hygienic conditions) at the University Hospital Zurich. Mice were housed in groups of 3 with unlimited access to food and water. Animal care and experiments were performed in accordance with the Swiss Animal Protection Law. All experiments were approved by the Veterinary Office of the Canton of Zurich (permit ZH168/2019). Our standard operating procedures allowed to repair surgical sutures one time in case of reopening. In our experience, female mice are less prone to wound reopening than male mice, and they can be regrouped after a period of single housing. Thus, we performed the experiment with female mice only.

Nerve crush surgery

Surgery was performed on the right hind limb of two-month-old female WT and PrnpZH3/ZH3 mice as described previously [22, 23]. Briefly, mice were injected with buprenorphinum (Temgesic, 0.1 mg/kg of bodyweight) prior to surgery. The surgery was performed under isoflurane anaesthesia. Fur was removed with an electric trimmer and the sciatic nerve was exposed at the height of the hip by making a small incision. The sciatic nerve was exposed by blunt dissection and crushed by squeezing firmly for 30 seconds with a Dumont S&T JF-5 forceps (FST tools) at the height of the sciatic notch. The tissue was repositioned, and the wound was sealed with a suture. Mice were administered buprenorphinum for analgesia during the first 2 postoperative days. Sciatic nerves from crushed and contralateral side were harvested at 5, 10, 12, 16 and 30 days post crush.

Nerve harvesting

Mice were sacrificed by cervical dislocation in deep anaesthesia. Sciatic nerves were embedded in the required fixation solution for morphological analysis or frozen in liquid nitrogen for protein analysis. After crush injury, the sciatic nerve distal to the crush site was divided in 3 parts (see S1 Fig). A segment distal to the crush site (3 mm) was used for electron microscopy (EM). The distal side of this segment was embedded facing the front of the block face for sectioning. Sections from 2 mm distal to the crush site were analysed by EM. The remaining sciatic nerve was cut in half and the more proximal segment was processed for immunofluorescence (IF) as described below. the nerve segment was positioned with the proximal side facing the front of the block face for sectioning. Thereby, the EM and IF images derived from a similar distance from the crush side. The most distal segment of the sciatic nerve was frozen in liquid nitrogen and used for protein analysis. On the contralateral side, the corresponding segments were collected in the same manner.

Western blot analysis

Sciatic nerves were homogenized using stainless-steel beads in ice-cold lysis buffer (phosSTOP (Sigma, 4906845001) and protease inhibitor (Sigma, 11836153001) in RIPA buffer). Debris was removed by centrifugation of the lysates for 10 min at 10’000 g. Protein concentration was measured with BCA assay (Thermo Scientific). 10 μg protein for each sample was boiled in 4 x LDS (Invitrogen) at 95°C for 5–10 min and loaded on a gradient 4–12% NuPAGE Bis-Tris gels (Invitrogen). After electrophoresis at 200 V, gels were transferred to PVDF membranes with the iBlot system (Life Technologies). Then, membranes were blocked with 5% SureBlock (LuBioScience GmbH, SB232010) in TBS-T. Incubation with primary antibodies was performed night at 4°C. After three washes for 10 min, membranes were incubated with secondary antibodies coupled to horseradish peroxidase for 1 h at room temperature (RT). Membranes were then washed and developed with Crescendo chemiluminescence substrate system (Sigma, WBLUR0500). Signals were detected using a Fusion Solo S imaging system (Vilber). The FusionCapt Advance software was used for densitometry. For quantification, the protein levels of each sample were normalized to the respective loading control (actin or calnexin) and expressed as fold change to the average WT levels. Before incubating membranes with the next primary antibody, stripping was performed with Restore Western Blot Stripping Buffer (Thermofisher, 20163) for 15 min at RT and membranes were washed two times in TBS-T. Each lane in the blots and each point in the graphs represents one sciatic nerve from one mouse. Original, uncropped images are shown in (S2 Fig). The following primary antibodies were used for western blotting: rabbit anti-GFAP (1:2000, Cell Signaling Technologies, 12389S), rabbit anti-c-Jun (1:1000, 9165s), rabbit anti-Calnexin (1:2000, Enzo, ADI-SPA-865-D), mouse anti-Actin (1:10’000, Milipore, MAB1501R). In addition, we used an in-house produced mouse monoclonal antibody (POM2) for detection of PrP [24]. The following horseradish peroxidase coupled secondary antibodies were used: anti-mouse IgG (1:10’000, Jackson Immuno Research, 115-035-003), anti-rabbit IgG (1:4000, Jackson Immuno Research, 111-035-003).

Morphological analysis by EM

Sciatic nerves were immersed in 4% glutaraldehyde in 0.1 M sodium phosphate buffer pH 7.4 immediately after dissection and incubated at 4°C overnight. Tissue was embedded in Epon using standard procedures. Further steps were performed as described [23]. Briefly, 99 nm sections were collected on ITO coverslips (Optics Balzers). Imaging for EM reconstruction of the entire sciatic nerve section was performed with either a Carl Zeiss Gemini Leo 1530 FEG or Carl Zeiss Merlin FEG scanning electron microscope attached to Atlas modules (Carl Zeiss). Adobe Photoshop CS5 was used for image analysis. The g-ratio corresponds to the ratio between axon diameter and fibre diameter. The axon diameter was derived from the axon area. The myelin thickness was measured at two different locations of the myelin ring. The average myelin thickness was added twice to the axon diameter to obtain the fibre diameter. For g-ratio quantification, three different locations on the cross section were chosen and at least 100 fibres per sample were analysed. The number of intact appearing myelin profiles, remyelinated fibres and the area covered by myelin debris was assessed manually on the entire cross section. The investigator was blinded as to the genotype of the mice for all analyses.

Immunofluorescence (IF)

Sciatic nerves were isolated as described above. The tissue was fixed in 4% paraformaldehyde overnight at 4°C. Then, the tissue was incubated in 30% sucrose solution and frozen in OCT compound. Cross-sections of 8 μM thickness were cut at the cryostat. After drying at room temperature (RT), sections were incubated in blocking buffer (10% normal goat serum, 0.5% bovine serum albumin (BSA), 0.3% Triton X-100 in PBS) for 1 h at RT. Blocking buffer was diluted 1:1 with PBS for incubation with primary antibodies at 4°C overnight. The following primary antibodies were used: rabbit anti-Ki67 (Abcam, ab15580, 1:1000), rabbit anti-c-Jun (Cell Signalling Technologies, 9165, 1:250), rabbit anti-S100 (Dako, Z0311, 1:250), mouse anti-S100 (Thermofisher, MA-12969, 1:50), rat anti-CD68 (Biorad, MCA1957, 1:200), rat anti-CD45 (BD Pharmagen 553078, 1:50), rabbit anti-Iba1 (Wako Biochemicals, 019–19741, 1:500). After three washes in PBS, slides were incubated with fluorophore-conjugated secondary antibodies (Alexa Fluor goat anti-rabbit 488 nm or 594 nm, goat anti-rat 594 nm or 647nm, goat anti-mouse 488 nm, Invitrogen) for 1 h at RT. Then, sections were washed in PBS, incubated with DAPI (1:10’000) to label nuclei for 10 min and mounted using Fluorescence mounting medium (Dako, S3023). Fluorescent images were recorded with a Leica SP5 Confocal Microscope. The original unaltered images from the figures are provided in (S3 and S4 Figs).

For quantification of IF images, ImageJ (version 1.52) was used. To count DAPI, c-Jun and ki67-positive nuclei, nuclei were defined using the threshold function. Counting was performed on binary images. For each marker, the same ImageJ macro was applied to all images from one time point. The number of ki67-positive or c-Jun-positive nuclei was normalized to the total number of DAPI-positive nuclei in the field of view. Macrophages were quantified as the total CD68-positive area in relation to the S100-positive area. Iba1-positive cells and CD45-positive cells were counted manually using ImageJ. For each time point, three animals per group were analysed. For each mouse, the mean value from quantification of 2–4 images from separate nerve sections was used for statistical analysis. The investigator was blinded as to the time point and the genotype of the mice.

Experimental design and statistical analysis

The sample size was chosen according to sample sizes used in previous publications performing western blot, IF and EM analyses of sciatic nerves [12, 25, 26]. Furthermore, it is in accordance with a sample size calculation based on the results from the CD68- and Iba1-immunohistochemistry studies reported in [12] (calculated with the G*power software version 3.1.9.7 with power 0.8, type I error rate 5%, effect size determined from [12] ranging from 2–6).

Statistical analysis was performed with GraphPad Prism software (version 8.4.2). We assumed normal distribution and equal variances of data but did not formally test this assumption due to small n values. Unpaired two-tailed t-test was used for comparison of two groups. For comparison of three or more groups, two-way ANOVA followed by Sidak’s multiple comparison test was used and multiplicity adjusted p-values were reported. P-values below 0.05 were considered statistically significant. P-values are indicated in graphs as *: p < 0.05. ns: not significant, p > 0.05. Error bars in graphs show SEM. No samples or data were omitted during the analyses. R (version 3.5.2) was used to generate the scatterplot visualizing the g-ratio analysis.

Results

PrP is not required for demyelination, repair Schwann cell generation and proliferation following nerve injury

To study the role of PrP in peripheral nerve regeneration, we performed sciatic nerve crush injuries in female PrnpZH3/ZH3 and WT mice and investigated the morphological and molecular stages of peripheral nerve repair. To avoid any interference of the demyelinating disease developed by ageing PrnpZH3/ZH3 mice, we performed the nerve crush injuries in mice at 2 months of age, when no morphological signs of demyelination can be detected [15, 21]. In particular, the number of endoneurial macrophages is not significantly increased in PrnpZH3/ZH3 mice at this age [21]. We crushed the sciatic nerve at the sciatic notch, and harvested the nerve segments distal to the injury site at 5, 10, 12, 16 and 30 days post crush (d.p.c). Additionally, we collected the uninjured contralateral sciatic nerves as controls. To ensure comparability between the groups, the sections harvested for the various analyses were taken from the same distance from the crush site as depicted in (S1 Fig).

First, we assessed if Schwann cells in PrnpZH3/ZH3 mice were able to properly transdifferentiate to repair Schwann cells. We investigated c-Jun as a molecular marker of repair Schwann cells [6] by immunofluorescence (IF) and western blotting (Fig 1a–1d). At 5 d.p.c. a strong upregulation of c-Jun was detected both in WT and PrnpZH3/ZH3 mice. c-Jun levels decreased at later time points post injury. In uninjured contralateral nerves, c-Jun protein levels were low and nuclear c-Jun staining in IF was very faint. We did not detect any significant differences in c-Jun levels between WT and PrnpZH3/ZH3 mice at 5, 10, 16 and 30 d.p.c.

Fig 1. Generation of repair Schwann cells.

Fig 1

(a) IF images of sciatic nerve cross sections from WT and PrnpZH3/ZH3 mice at 5 and 10 d.p.c. showed upregulation of c-Jun. Nuclear c-Jun expression was faint in the uninjured sciatic nerve of a WT mouse. Channels for c-Jun and DAPI are shown separately. Scale bar 50 μM. (b) Quantification of c-Jun positive nuclei revealed no significant differences between WT and PrnpZH3/ZH3 mice at 5, 16 and 30 d.p.c, nor between uninjured nerves from WT and PrnpZH3/ZH3 mice (two-way ANOVA, Sidak’s multiple comparisons test, p > 0.05). (c) Western blot of lysates from crushed and uninjured (contralateral) sciatic nerves at 5, 10 and 16 d.p.c. showed a pronounced upregulation of GFAP and total c-Jun protein levels both in WT and PrnpZH3/ZH3 mice. Also, a slight upregulation of actin was detected in crushed nerves. (d) For quantification, GFAP and c-Jun were normalized to actin and expressed as fold change to the average level of crushed WT nerves. No statistically significant difference was detected between WT and PrnpZH3/ZH3 mice at the investigated time points (two-way ANOVA, Sidak’s multiple comparisons test, p > 0.05). (e) Western blot detecting low GFAP levels in uninjured sciatic nerves from WT (n = 6) and PrnpZH3/ZH3 mice (n = 6) sacrificed at 5, 16 and 30 d.p.c. GFAP levels were higher in PrnpZH3/ZH3 sciatic nerves when compared to WT nerves. Blotting with POM2, a monoclonal anti-PrP antibody, detected PrP in WT but not in PrnpZH3/ZH3 sciatic nerves, confirming the absence of PrP in PrnpZH3/ZH3 mice.

Next, we examined the expression of glial fibrillary acidic protein (GFAP). In the uninjured adult nerve, GFAP is mainly expressed by non-myelinating Schwann cells [27]. After injury, a strong upregulation of GFAP can be detected in sciatic nerves [28, 29], which is part of the Schwann cell injury response and contributes to efficient nerve regeneration [28, 30]. We quantified total sciatic nerve GFAP levels by western blotting (Fig 1c and 1d). GFAP levels were increased in crushed nerves compared to uninjured nerves, but no significant difference in GFAP levels was detected between PrnpZH3/ZH3 and WT mice at the investigated time points. At 5 d.p.c. GFAP levels in uninjured PrnpZH3/ZH3 mice appeared higher than in WT mice. By comparing GFAP expression in uninjured PrnpZH3/ZH3 and WT nerves (Fig 1e) we found that PrnpZH3/ZH3 mice had on average a two-fold higher baseline GFAP level when compared to WT mice (relative increase to WT GFAP level as quantified from Fig 1e: WT 1.00 ± 0.17 (6); PrnpZH3/ZH3 2.05 ± 0.09 (6); mean ± SEM (n); p = 0.0003, unpaired t-test), which is in line with our previously published findings [31].

Ki67 staining in crushed sciatic nerves showed that proliferation was highest at 5 d.p.c. both in WT and PrnpZH3/ZH3 mice, and no significant difference in the proliferation index was detected between WT and PrnpZH3/ZH3 mice at any of the time points investigated (Fig 2a and 2b). To investigate which cell types contribute to proliferating cells, we performed co-staining with S100 for Schwann cells and CD68 for macrophages in nerve sections from 5 d.p.c. Most ki67-positive proliferating cells belonged to Schwann cells, whereas only few macrophages were positive for ki67. This indicated that macrophages did not significantly contribute to the population of proliferating cells at 5 d.p.c.

Fig 2. Proliferation and demyelination in the early stages after crush injury.

Fig 2

(a) IF images of sciatic nerve cross sections from WT and PrnpZH3/ZH3 mice at 5 d.p.c. revealed many ki67-positive proliferating cells. The contralateral uninjured nerve from a WT mouse showed no proliferating cells. Channels for ki67 and DAPI are shown separately. Scale bar: 50 μM. (b) Ki67-proliferation index (% ki67-positive nuclei) as quantified from IF images was highest at 5 d.p.c. and decreased at later stages post crush injury. No significant differences were detected between WT and PrnpZH3/ZH3 mice at 5, 16 and 30 d.p.c. (two-way ANOVA, Sidak’s multiple comparisons test, p > 0.05). n.s. = not significant. (c) IF images from crushed sciatic nerves at 5 d.p.c. stained for ki67, S100, CD68 and DAPI. The majority of ki67-positive nuclei colocalize with S100-positive Schwann cells (white arrows), whereas only few CD68-positive macrophages have ki67-positive nuclei (white triangles). Scale bar 25 μM. (d) Quantification of intact appearing myelin profiles at 5 d.p.c. from EM images revealed no significant difference between WT and PrnpZH3/ZH3 mice (WT 191 ± 38 (3); PrnpZH3/ZH3 244 ± 68 (3); mean ± SEM (n); p = 0.5277; unpaired t-test). (e) EM images of sciatic nerves from WT and PrnpZH3/ZH3 mice at 5 d.p.c. showed extensive demyelination and few intact appearing myelin rings (white asterix). Scale bar: 5 μm.

In the early stages after nerve crush, repair Schwann cells are the main effectors of myelin breakdown and digestion [32]. Using electron microscopy (EM) we investigated the extent of demyelination by counting the number of myelin profiles that still appeared intact at 5 d.p.c. (Fig 2d and 2e). The number of intact appearing myelin profiles per sciatic nerve cross section was not significantly altered in PrnpZH3/ZH3 mice when compared to WT mice, indicating that the initial myelin breakdown is neither slowed nor accelerated in the absence of PrP.

Collectively, these results suggested that PrP is not required for generation and function of repair Schwann cells after nerve crush injury.

PrP is not required for macrophage recruitment after peripheral nerve injury

Blood derived macrophages are recruited to the injured nerve via chemokines secreted by Schwann cells and mesenchymal cells [9]. Together with resident endoneurial macrophages, they contribute to debris clearance and repair after injury [33]. We performed IF for the macrophage marker CD68 to investigate if PrP is playing a role in macrophage recruitment (Fig 3a and 3b). While uninjured nerves were basically devoid of CD68-positive cells (Fig 3b), crushed sciatic nerves were infiltrated by numerous macrophages (Fig 3a). In both genotypes, macrophages were rounded and displayed a phagocytic, foamy appearance. We quantified the area covered by CD68-positive cells in relation to the S100-positive area (Fig 3c). Macrophage accumulation in the endoneurium displayed a time course which is consistent with published findings [33, 34] and showed no significant difference between WT and PrnpZH3/ZH3 sciatic nerves at any of the investigated time points.

Fig 3. Recruitment of inflammatory cells.

Fig 3

(a) IF images of sciatic nerve cross sections from WT and PrnpZH3/ZH3 mice at 10 and 16 d.p.c. showed pronounced infiltration by CD68-positive macrophages. White triangles: CD68-positive macrophages. White arrows: S100-positive Schwann cells. Squares indicate region selected for blown-up images of macrophages shown in the lower panels. Scale bar 25 μM. (b) IF images of uninjured (contralateral) sciatic nerve showed no infiltration by macrophages. Scale bar 25 μM. (c) The extent of macrophage infiltration (quantified as the ratio of the CD68-positive area to the S100-positive area in IF images) was not significantly different when comparing WT and PrnpZH3/ZH3 mice at all investigated time points (two-way ANOVA, Sidak’s multiple comparisons test, p > 0.05). (d) IF images of sciatic nerve cross section from WT and PrnpZH3/ZH3 mice at 10 d.p.c showed infiltration by Iba1-positive macrophages (white triangles) and CD45-positive lymphocytes (white asterix). Scale bar 25 μM. (e) The number of macrophages as quantified from IF images was not significantly different when comparing WT and PrnpZH3/ZH3 mice (WT 100 ± 3.90 (3); PrnpZH3/ZH3 99.32 ± 6.80 (3); percentage of average macrophage number in WT; mean ± SEM (n); p = 0.9352; unpaired t-test). (f) The number of lymphocytes as quantified from IF images was not significantly different when comparing WT and PrnpZH3/ZH3 mice at 10 d.p.c. (WT 100 ± 8.88 (3); PrnpZH3/ZH3 72.63 ± 7.69 (3); percentage of average lymphocyte number in WT; mean ± SEM (n); p = 0.0803; unpaired t-test). n.s. = not significant.

Staining for Iba1, another macrophage marker, revealed a picture similar to CD68-staining (Fig 3d) and there was no significant difference in the number of Iba1-positive macrophages between WT and PrnpZH3/ZH3 mice at 10 d.p.c. (Fig 3e).

In addition to macrophages, the endoneurial inflammatory infiltrate comprised some CD45-positive lymphocytes with no statistically significant difference between WT and PrnpZH3/ZH3 mice at 10 d.p.c. (Fig 3d and 3f). These results suggest that the lack of PrP does not affect injury-induced recruitment of macrophages and lymphocytes to the peripheral nerves.

Remyelination is not impaired in PrnpZH3/ZH3 mice

To investigate if PrP is required in later stages of nerve repair, we assessed remyelination after nerve crush injury by EM. We first analysed the crushed sciatic nerves at 12 d.p.c., when regrown axons are undergoing remyelination by redifferentiated Schwann cells (Fig 4). EM analysis revealed robust remyelination in both WT and PrnpZH3/ZH3 nerves with no statistically significant difference between genotypes (WT 85.88 ± 1.39 (3), PrnpZH3/ZH3 88.56 ± 1.28 (3), percent of remyelinated axons; mean ± SEM (n), p = 0.2282; unpaired t-test). No gross morphological differences were noted between genotypes. At 30 d.p.c. some myelin debris was still present both in WT and PrnpZH3/ZH3 mice (Fig 5a and 5d). The amount of remaining debris was similar in both genotypes (WT 2.62 ± 0.37 (3), PrnpZH3/ZH3 2.55 ± 0.29 (3), percentage of total sciatic nerve area covered by myelin debris; mean ± SEM (n), p = 0.8911; unpaired t-test). To determine the thickness of the myelin sheath, we performed g-ratio analysis at 10 and 30 d.p.c. In both genotypes, the g-ratio was higher in sciatic nerves at 10 d.p.c (WT 0.88 ± 0.002 (335), PrnpZH3/ZH3 0.88 ± 0.002 (323), g-ratio; mean ± SEM (number of myelinated axons quantified), p = 0.2745; unpaired t-test) than at 30 d.p.c. (WT 0.73 ± 0.003 (319), PrnpZH3/ZH3 0.72 ± 0.003 (423), g-ratio; mean ± SEM (n), p = 0.4419; unpaired t-test), indicating an increase in myelin thickness. There was no significant difference in myelin thickness as assessed by g-ratio analysis between WT and PrnpZH3/ZH3 mice at either of the two time points (quantification for 30 d.p.c. shown in Fig 5b and 5c). Finally, we counted the total number of myelination-competent axons (with a diameter larger than 1 μm) in sciatic nerve cross sections (Fig 5e). The total number of axons was not significantly different between WT and PrnpZH3/ZH3 mice at 12 d.p.c. or 30 d.p.c. (12 d.p.c.: WT 3115 ± 85 (3), PrnpZH3/ZH3 3134 ± 180 (3), number of axons; mean ± SEM, p > 0.999. 30 d.p.c.: WT 4198 ± 33 (3), PrnpZH3/ZH3 4245 ± 62 (3), number of axons; mean ± SEM, p = 0.9385; one-way ANOVA, Sidak’s multiple comparisons test), whereas a significant increase in axon numbers was detected in both genotypes when comparing 12 to 30 d.p.c. (p = 0.002 and p = 0.001 for WT and PrnpZH3/ZH3 mice, respectively).

Fig 4. Remyelination at 12 d.p.c.

Fig 4

EM images of sciatic nerves from WT and PrnpZH3/ZH3 mice at 12 d.p.c. revealed robust remyelination in both genotypes. Scale bar 5 μm.

Fig 5. Remyelination at 30 d.p.c.

Fig 5

(a) EM images of sciatic nerves from WT and PrnpZH3/ZH3 mice at 30 d.p.c. showed remyelinated axons and little myelin debris remaining. m: myelinated axons, *: non-myelinated axon with > 1 μm diameter, white arrowhead: myelin debris. Scale bar 5 μm. (b, c) G-ratio analysis in WT (n = 3) and PrnpZH3/ZH3 (n = 3) mice at 30 d.p.c. Quantification of > 100 myelinated axons per mouse. Straight lines in (b) show linear regression. No significant difference in mean g-ratio (c) was detected between genotypes (unpaired t-test, p > 0.05). (d) Quantification of area covered by myelin debris at 30 d.p.c. showed no significant difference between WT (n = 3) and PrnpZH3/ZH3 (n = 3) mice (unpaired t-test, p > 0.05). (e) The total number of myelination competent axons with diameter > 1μm increased from 12 d.p.c. to 30 d.p.c. No significant difference was detected between WT and PrnpZH3/ZH3 mice at 12 or 30 d.p.c. (p > 0.05; one-way ANOVA, Sidak’s multiple comparisons test) *: p < 0.05. n.s. = not significant.

Discussion

Adgrg6 is expressed in Schwann cells and was shown to have autonomous and non-autonomous functions in peripheral nerve repair [12, 13]. PrP is an agonist of Adgrg6 on Schwann cells [14]. We therefore hypothesized that the lack of PrP causes similar defects in peripheral nerve repair as the knockout of Adgrg6. To evaluate our hypothesis, we performed sciatic nerve crush injuries in female WT and PrnpZH3/ZH3 mice and investigated the stages of repair by EM, IF and western blotting. Contrary to our expectations, we detected no differences in macrophage recruitment and remyelination when comparing sciatic nerve regeneration in PrnpZH3/ZH3 mice to WT mice, indicating that PrP is not responsible to induce these Adgrg6-mediated processes. Furthermore, the extent and timing of c-Jun upregulation, demyelination and Schwann cell proliferation were similar in PrnpZH3/ZH3 mice when compared to WT mice at all investigated time points. Our results thus suggest that PrP is not required for injury-induced peripheral nerve de- and remyelination. This may be either because PrP plays no major role in the peripheral nerve repair processes, or because other molecules can compensate for the lack of PrP. Alternatively, Adgrg6 may exhibit a basal constitutive activity sufficient to guarantee nerve repair in the absence of any agonist. Regarding the first point, PrP is dispensable for normal development of the PNS and only required for long-term maintenance of the myelin sheath [15]. Many of the repair processes after nerve injury recapitulate developmental processes [5] and it is possible that PrP is simply not required for peripheral nerve repair. As to the second point, PrP is thought to function in myelin maintenance via activation of Adgrg6 on Schwann cells. Adgrg6 is involved in peripheral nerve repair, as was suggested by deficits in macrophage recruitment and remyelination after peripheral nerve injury in conditional Adgrg6 knockout mice. Thus, Adgrg6 must sustain its function in nerve repair independent of PrP, for example via activation by other ligands such as collagen IV [35] and laminin-211 [36].

In a further possible scenario, PrP might play contrasting roles in different cells types during the repair processes. Theoretically, the effects of PrP in different cell types may cancel each other out in a transgenic mouse with global PrP knockout as was used in the present study. However, considering that the peripheral nerve repair processes are regulated by a highly orchestrated, balanced interaction between many cell types, we feel that this is an unlikely scenario.

We have previously described that PrnpZH3/ZH3 mice exhibit an early upregulation of repair Schwann cell markers in sciatic nerves, which probably represents an early sign of the peripheral nerve disease [31]. In the present study, we confirmed that the 2–3 months old PrnpZH3/ZH3 mice undergoing crush injury showed a two-fold upregulation of GFAP in their uninjured sciatic nerves when compared to WT mice. The absolute GFAP levels after crush injury were similar in both genotypes, and the elevated baseline GFAP level in PrnpZH3/ZH3 mice did not interfere with regeneration. Whereas defective Schwann cell proliferation and delayed regeneration after nerve crush injury have been described in GFAP knockout mice [30, 37], the effect of GFAP overexpression on PNS development, maintenance or repair has not been investigated [38, 39]. GFAP gain-of-function mutations cause Alexander disease, a rare astrogliopathy characterized by accumulation of GFAP in the central nervous system [40]. Development of a peripheral demyelinating neuropathy was reported in an 8-year-old patient with Alexander disease [41], but apart from this case, there is currently no compelling evidence that GFAP accumulation or overexpression contributes to or causes PNS degeneration. The finding that sciatic nerve repair is not impaired in PrnpZH3/ZH3 mice despite increased baseline GFAP levels might be interpreted as an indication that a baseline elevation in GFAP is still compatible with peripheral nerve regeneration.

Limitations

While we provide molecular and morphological analyses of injury-induced Schwann cell transdifferentiation and proliferation, de- and remyelination as well as recruitment of inflammatory cells, we have not investigated other aspects of peripheral nerve repair such as axon regeneration and restoration of neuromuscular junctions. We quantified the total number of axons in sciatic nerves distal to the crush site and detected a robust increase in the number of large axons (diameter > 1 μm), indicating successful regeneration. However, we did not analyse the regeneration of axons at more distal sites nor the reinnervation of neuromuscular junctions after injury. Previous studies showed impaired reinnervation of neuromuscular junctions and defects in terminal Schwann cell responses in Adgrg6 deficient mice [12, 13]. We did not investigate whether PrP is involved in these processes. Furthermore, no functional analyses such as toe spreading index, walking track analysis or electrophysiological investigations were performed in the present study. The lack of morphological and molecular deficits at various time points post crush does not rule out (transient) differences in functional recovery between WT and PrnpZH3/ZH3 mice.

Our study was performed with a small number of animals (n = 3 per genotype and time point). By performing the analyses at multiple time points and by combining multiple complementary readouts we aimed to increase the validity of our results. While the small n warrants for caution when interpreting the results of the study, the fact that all analyses consistently showed no significant effect of PrP strengthens our conclusion. Furthermore, we are confident that a regeneration deficit of the magnitude detected in Adgrg6 knockout mice [12] should not have remained undetected in our study. Smaller defects, as well as transient functional deficits or impairment of neuromuscular junction restoration may however still be present in PrnpZH3/ZH3 mice.

Conclusions

While the results of our study do not support the hypothesis that PrP is required to activate Adgrg6-mediated macrophage recruitment and remyelination after nerve crush injury, they do not rule out an ancillary, non-essential role for such interactions. Furthermore, it is possible that additional, hitherto undiscovered Adgrg6 ligands exist. The importance of such ligands to peripheral-nerve repair may vary in different species. Therefore, the negative results reported here should not discourage researchers from exploring Adgrg6 activation as a possible adjuvant therapy for peripheral nerve repair.

Supporting information

S1 Fig. Nerve harvest after crush injury.

The sciatic nerve was crushed using a forceps at the sciatic notch. For harvesting, the nerve was cut at 3 mm distal to the crush side. The proximal segment was embedded for electron microscopy (EM), the distal segment was used for immunofluorescence (IF) and western blotting.

(TIFF)

S2 Fig. Original western blot images.

The uncropped blots have been inverted using the Affinity Photo software. Molecular weight markers used are indicated in kilo Dalton (kD). The arrows indicate the order in which the blots were incubated with primary antibodies. Stripping was performed before each incubation. The dashed line in blot Fig 1e indicates that the membrane was cut, and the upper and lower half were incubated with different antibodies.

(TIF)

S3 Fig. Original immunofluorescence images.

The separate channels for each image are shown without alterations of contrast or brightness and no cropping.

(TIF)

S4 Fig. Original immunofluorescence images.

The separate channels for each image are shown without alterations of contrast or brightness and no cropping.

(TIF)

S1 Table. Raw data used for graphs and calculations.

(XLSX)

Acknowledgments

We thank Dr. Jorge A. Pereira for teaching, supervision and technical help with EM imaging, Marigona Imeri and Irina Abakumova for their valuable technical help with revision experiments, and Alexander Henzi for support with R programming and statistical analyses.

Data Availability

All relevant data are within the paper and its Supporting information files.

Funding Statement

AA is the recipient of a Swiss National Research Foundation Sinergia grant (CRSII5 183563). http://www.snf.ch/en/funding/programmes/sinergia/Pages/default.aspx. The funders did not play any role in study design, data collection, analysis, preparation of the manuscript or decision to publish.

References

  • 1.Monk KR, Feltri ML, Taveggia C. New insights on schwann cell development: Schwann Cell Development. Glia 2015;63:1376–93. 10.1002/glia.22852 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Raphael AR, Talbot WS. New insights into signaling during myelination in zebrafish. Curr Top Dev Biol 2011;97:1–19. 10.1016/B978-0-12-385975-4.00007-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Brosius Lutz A, Barres BA. Contrasting the Glial Response to Axon Injury in the Central and Peripheral Nervous Systems. Developmental Cell 2014;28:7–17. 10.1016/j.devcel.2013.12.002 [DOI] [PubMed] [Google Scholar]
  • 4.Jessen KR, Mirsky R. The repair Schwann cell and its function in regenerating nerves: Repair Schwann cell and its function in regenerating nerves. J Physiol 2016;594:3521–31. 10.1113/JP270874 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Nocera G, Jacob C. Mechanisms of Schwann cell plasticity involved in peripheral nerve repair after injury. Cell Mol Life Sci 2020. 10.1007/s00018-020-03516-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Arthur-Farraj PJ, Latouche M, Wilton DK, Quintes S, Chabrol E, Banerjee A, et al. c-Jun Reprograms Schwann Cells of Injured Nerves to Generate a Repair Cell Essential for Regeneration. Neuron 2012;75:633–47. 10.1016/j.neuron.2012.06.021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Arthur-Farraj PJ, Morgan CC, Adamowicz M, Gomez-Sanchez JA, Fazal SV, Beucher A, et al. Changes in the Coding and Non-coding Transcriptome and DNA Methylome that Define the Schwann Cell Repair Phenotype after Nerve Injury. Cell Reports 2017;20:2719–34. 10.1016/j.celrep.2017.08.064 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Bosse F, Hasenpusch-Theil K, Küry P, Müller HW. Gene expression profiling reveals that peripheral nerve regeneration is a consequence of both novel injury-dependent and reactivated developmental processes: Expression profiling during peripheral nerve regeneration. Journal of Neurochemistry 2006;96:1441–57. 10.1111/j.1471-4159.2005.03635.x [DOI] [PubMed] [Google Scholar]
  • 9.Toma JS, Karamboulas K, Carr MJ, Kolaj A, Yuzwa SA, Mahmud N, et al. Peripheral Nerve Single-Cell Analysis Identifies Mesenchymal Ligands that Promote Axonal Growth. ENeuro 2020;7 10.1523/ENEURO.0066-20.2020 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Monk KR, Naylor SG, Glenn TD, Mercurio S, Perlin JR, Dominguez C, et al. A G Protein-Coupled Receptor Is Essential for Schwann Cells to Initiate Myelination. Science 2009;325:1402–5. 10.1126/science.1173474 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Monk KR, Oshima K, Jors S, Heller S, Talbot WS. Gpr126 is essential for peripheral nerve development and myelination in mammals. Development 2011;138:2673–80. 10.1242/dev.062224 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Mogha A, Harty BL, Carlin D, Joseph J, Sanchez NE, Suter U, et al. Gpr126/Adgrg6 Has Schwann Cell Autonomous and Nonautonomous Functions in Peripheral Nerve Injury and Repair. J Neurosci 2016;36:12351–67. 10.1523/JNEUROSCI.3854-15.2016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Jablonka-Shariff A, Lu C-Y, Campbell K, Monk KR, Snyder-Warwick AK. Gpr126/Adgrg6 contributes to the terminal Schwann cell response at the neuromuscular junction following peripheral nerve injury. Glia 2019. 10.1002/glia.23769 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Küffer A, Lakkaraju AKK, Mogha A, Petersen SC, Airich K, Doucerain C, et al. The prion protein is an agonistic ligand of the G protein-coupled receptor Adgrg6. Nature 2016;536:464–8. 10.1038/nature19312 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Bremer J, Baumann F, Tiberi C, Wessig C, Fischer H, Schwarz P, et al. Axonal prion protein is required for peripheral myelin maintenance. Nat Neurosci 2010;13:310–8. 10.1038/nn.2483 [DOI] [PubMed] [Google Scholar]
  • 16.Bendheim PE, Brown HR, Rudelli RD, Scala LJ, Goller NL, Wen GY, et al. Nearly ubiquitous tissue distribution of the scrapie agent precursor protein. Neurology 1992;42:149–149. 10.1212/wnl.42.1.149 [DOI] [PubMed] [Google Scholar]
  • 17.Prusiner S. Novel proteinaceous infectious particles cause scrapie. Science 1982;216:136–44. 10.1126/science.6801762 [DOI] [PubMed] [Google Scholar]
  • 18.Aguzzi A, De Cecco E. Shifts and drifts in prion science. Science 2020;370:32–4. 10.1126/science.abb8577 [DOI] [PubMed] [Google Scholar]
  • 19.Sakaguchi S, Katamine S, Nishida N, Moriuchi R, Shigematsu K, Sugimoto T, et al. Loss of cerebellar Purkinje cells in aged mice homozygous for a disrupted PrP gene. Nature 1996;380:528–31. 10.1038/380528a0 [DOI] [PubMed] [Google Scholar]
  • 20.Wulf M-A, Senatore A, Aguzzi A. The biological function of the cellular prion protein: an update. BMC Biol 2017;15:34 10.1186/s12915-017-0375-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Nuvolone M, Hermann M, Sorce S, Russo G, Tiberi C, Schwarz P, et al. Strictly co-isogenic C57BL/6J-Prnp-/- mice: A rigorous resource for prion science. J Exp Med 2016;213:313–27. 10.1084/jem.20151610 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Gökbuget D, Pereira JA, Opitz L, Christe D, Kessler T, Marchais A, et al. The miRNA biogenesis pathway prevents inappropriate expression of injury response genes in developing and adult Schwann cells. Glia 2018;66:2632–44. 10.1002/glia.23516 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Pereira JA, Gerber J, Ghidinelli M, Gerber D, Tortola L, Ommer A, et al. Mice carrying an analogous heterozygous dynamin 2 K562E mutation that causes neuropathy in humans develop predominant characteristics of a primary myopathy. Human Molecular Genetics 2020;29:1253–73. 10.1093/hmg/ddaa034 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Polymenidou M, Moos R, Scott M, Sigurdson C, Shi Y, Yajima B, et al. The POM Monoclonals: A Comprehensive Set of Antibodies to Non-Overlapping Prion Protein Epitopes. PLoS ONE 2008;3:e3872 10.1371/journal.pone.0003872 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Norrmén C, Figlia G, Pfistner P, Pereira JA, Bachofner S, Suter U. mTORC1 Is Transiently Reactivated in Injured Nerves to Promote c-Jun Elevation and Schwann Cell Dedifferentiation. J Neurosci 2018;38:4811–28. 10.1523/JNEUROSCI.3619-17.2018 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Gerber D, Ghidinelli M, Tinelli E, Somandin C, Gerber J, Pereira JA, et al. Schwann cells, but not Oligodendrocytes, Depend Strictly on Dynamin 2 Function. ELife 2019;8:e42404 10.7554/eLife.42404 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Jessen KR, Morgan L, Stewart HJ, Mirsky R. Three markers of adult non-myelin-forming Schwann cells, 217c(Ran-1), A5E3 and GFAP: development and regulation by neuron-Schwann cell interactions. Development 1990;109:91–103. [DOI] [PubMed] [Google Scholar]
  • 28.Jessen KR, Mirsky R. Negative regulation of myelination: Relevance for development, injury, and demyelinating disease. Glia 2008;56:1552–65. 10.1002/glia.20761 [DOI] [PubMed] [Google Scholar]
  • 29.Zhang S, Wu W, Yang K, Chen Y, Liu H. Phenotypic changes of Schwann cells on the proximal stump of injured peripheral nerve during repair using small gap conduit tube. Neural Regen Res 2017;12:1538 10.4103/1673-5374.215266 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Triolo D. Loss of glial fibrillary acidic protein (GFAP) impairs Schwann cell proliferation and delays nerve regeneration after damage. Journal of Cell Science 2006;119:3981–93. 10.1242/jcs.03168 [DOI] [PubMed] [Google Scholar]
  • 31.Henzi A, Senatore A, Lakkaraju AKK, Scheckel C, Mühle J, Reimann R, et al. Soluble dimeric prion protein ligand activates Adgrg6 receptor but does not rescue early signs of demyelination in PrP-deficient mice. PLoS ONE 2020;15:e0242137 10.1371/journal.pone.0242137 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Gomez-Sanchez JA, Carty L, Iruarrizaga-Lejarreta M, Palomo-Irigoyen M, Varela-Rey M, Griffith M, et al. Schwann cell autophagy, myelinophagy, initiates myelin clearance from injured nerves. Journal of Cell Biology 2015;210:153–68. 10.1083/jcb.201503019 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Mueller M, Leonhard C, Wacker K, Ringelstein EB, Okabe M, Hickey WF, et al. Macrophage Response to Peripheral Nerve Injury: The Quantitative Contribution of Resident and Hematogenous Macrophages. Lab Invest 2003;83:175–85. 10.1097/01.lab.0000056993.28149.bf [DOI] [PubMed] [Google Scholar]
  • 34.Taskinen HS, Röyttä M. The dynamics of macrophage recruitment after nerve transection. Acta Neuropathologica 1997;93:252–9. 10.1007/s004010050611 [DOI] [PubMed] [Google Scholar]
  • 35.Paavola KJ, Sidik H, Zuchero JB, Eckart M, Talbot WS. Type IV collagen is an activating ligand for the adhesion G protein-coupled receptor GPR126. Science Signaling 2014;7:ra76–ra76. 10.1126/scisignal.2005347 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Petersen SC, Luo R, Liebscher I, Giera S, Jeong S-J, Mogha A, et al. The Adhesion GPCR GPR126 Has Distinct, Domain-Dependent Functions in Schwann Cell Development Mediated by Interaction with Laminin-211. Neuron 2015;85:755–69. 10.1016/j.neuron.2014.12.057 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Berg A, Zelano J, Pekna M, Wilhelmsson U, Pekny M, Cullheim S. Axonal Regeneration after Sciatic Nerve Lesion Is Delayed but Complete in GFAP- and Vimentin-Deficient Mice. PLoS ONE 2013;8:e79395 10.1371/journal.pone.0079395 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Hagemann TL, Gaeta SA, Smith MA, Johnson DA, Johnson JA, Messing A. Gene expression analysis in mice with elevated glial fibrillary acidic protein and Rosenthal fibers reveals a stress response followed by glial activation and neuronal dysfunction. Human Molecular Genetics 2005;14:2443–58. 10.1093/hmg/ddi248 [DOI] [PubMed] [Google Scholar]
  • 39.Messing A, Head MW, Galles K, Galbreath EJ, Goldman JE, Brenner M. Fatal encephalopathy with astrocyte inclusions in GFAP transgenic mice. Am J Pathol 1998;152:391–8. [PMC free article] [PubMed] [Google Scholar]
  • 40.Messing A, Brenner M, Feany MB, Nedergaard M, Goldman JE. Alexander Disease. Journal of Neuroscience 2012;32:5017–23. 10.1523/JNEUROSCI.5384-11.2012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Chinthaparthi S, McDonald K, Davis L. A case of Alexander disease with peripheral neuropathy associated with a novel mutation (P3.326). Neurology 2018;90:P3.326. [Google Scholar]

Decision Letter 0

Simone Di Giovanni

8 Dec 2020

PONE-D-20-33989

The prion protein is not required for peripheral nerve repair after crush injury

PLOS ONE

Dear Dr. Aguzzi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jan 15 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Simone Di Giovanni

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2.PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Schwann cell-specific loss of GPR126/Adgrg6 (for which PrPc is one interactor) results in a variety of defects in repair after peripheral nerve injury. In this work, Henzi and Aguzzi test the hypothesis that PRPc interactions with GPR126/Adgrg6 are responsible for some of these effects on peripheral nerve repair, by investigating the time course of demyelination and remyelination of the mouse sciatic nerve after crush injury in wt and PrPc null mice (PrnpZH3/ZH3). Examining demyelination, generation of “repair” Schwann cells, recruitment of macrophages to the injured nerve, and remyelination of axons 3mm from the crush site, they found no differences between wt and PrPc null animals up to 30 days after injury (except for a baseline difference in Schwann cell GFAP expression). The hypothesis tested is reasonable and clearly stated, and the data are carefully acquired and (mostly) clearly presented. The authors’ conclusion, that PrPc is not required for those aspects of repair that they studied, seems likely to be valid. For me, however, there are two main issues that should be addressed in order for this manuscript to be accepted. First, some experiments suffer from a lack of statistical power and other design/presentation issues, and second, a major aspect of nerve repair (axonal regeneration and NMJ re-formation) goes completely unexamined.

Issues with study design:

1) Why did the authors choose females and not males? Why use two months old animals rather than adult (3-6 months) mice? (3 months old mice were used for the GPR126 study)

2) There are in general 3 animals/group; was this value of N chosen based on power analyses? If so, what were the effect sizes, variances, and desired power used in the analyses? This low value of N has implications for their conclusions. Some examples follow.

3) It is clear that they failed to find differences in Figure 1, but the variance is sufficiently high that one would guess a substantially higher N would need to be sampled to detect differences smaller than a few-fold; this is also true for Figure 2b (KI67 data).

4) In Figure 3, the idea that macrophage recruitment peaked at 10 days postcrush cannot be supported by the data presented; it appears that days 10 and 16 are indistinguishable and may (or may not) be different from day 5 and day 30, but these statistical comparisons are not made.

5) If the authors decide not to perform further experiments, they should perform power analyses and provide the results in the paper, so that the strength of their conclusions can be judged.

6) Minor note: I suggest plotting 95% confidence intervals rather than SEMs, which are not really meaningful for N=3.

7) Figure S2. The main purpose of providing whole blots for examination is to judge the degree to which one can be confident of antibody performance. This is quite difficult with the current figure. As one example, the calnexin blot shows a marked calnexin band near the bottom of the gel, even though this is a 90 kD protein. The entire gels should be shown, and the positions of all MW markers demarcated with arrows, rather than using an asterisk to denote the general area of the blot where the band of interest is said to migrate. Additionally, for reviewer purposes, these blots should be shown after incubation with a single primary antibody, not multiple antibodies. Finally, the methods used to validate the antibodies used are not described. A statement is made that the asterisks mark “specific” bands, but no justification is provided for the apparent assumption that bands migrating at different molecular weights from the asterisks are “non-specific” as opposed to specific but non-desired.

Missing study elements:

8) The loss of GPR126/Adgrg6 function, specifically in Schwann cells, results in non-cell autonomous defects in axon regeneration and neuromuscular synapse formation. Clearly, axon regeneration is a sine qua non for peripheral nerve repair. However, neither axon regeneration nor NMJ reformation were examined in the current manuscript. Therefore, the statement that “PrP is dispensable for peripheral nerve repair” cannot be supported by the data provided. These experiments should be performed (ideally) or the conclusion statements should be modified.

Reviewer #2: Major points

1.) previous results by the same group (e.g. Nuvolone et al 2016) are not sufficiently mentioned and discussed in the light of the new data

2.) the mouse model is not adequately introduced: I assume it is a constitutive mouse mutant with PrP deletion in all cell types? Where are deletion phenotypes expected? Neurons and/or Schwann cells? This has to be discussed carefully.

3.) Data frequently rely on only single markers, e.g. c-Jun used for repair Schwann cells. Other markers should be used to confirm this result. Same is true for inflammation markers: here e.g. Iba1 and CD45 could also be used

4.) The authors state that GFAP is used as a Schwann cell marker, a statement not referenced and not entirely true. Typically, it is used as marker for astrocytes.

5.) The authors show altered GFAP expression between wt and mutant for the baseline. An alternative explanation to the one given by the authors might be that Prp suppresses neuroinflammation in wt mice. Please comment.

6.) For the Ki67 no co-staining with cellular markers is provided, so it is unclear in which cell type cell proliferation occurs. Co-localization experiments should be performed.

7.) For the CD68 marker ,authors previously (Nuvolone et al) described differences between wt and ko in baseline (Fig. 3b). Why is this not observed in the current study?

8.) The authors do not employ any functional assays to monitor nerve regeneration which limits their data interpretation. This limitation should be clearly stressed.

9.) Results and quantification in Fig. 1e seem mainly to rely on unequal loading as depicted by calnexin. Please comment.

10.) Numbers of animals at each timepoint are rather low (e.g. N=3). For instance in Fig. 2b there are 3 animals with one clear outlier. However, I see the point that authors include several timepoints. Nevertheless, low N-number should be discussed.

11.) No quantification for data in Fig. 2c is provided which should be included.

Minor points

1.) the introduction is overall very short and does not provide sufficient background

2.) In the figures author should designate mutant mice with mutant rather than simply ZH3

3.) Fig. 1b should also include uninjured even if values are zero

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Jan 22;16(1):e0245944. doi: 10.1371/journal.pone.0245944.r002

Author response to Decision Letter 0


21 Dec 2020

Response to Reviewers

Rebuttal letter [PONE-D-20-33989]

We thank the reviewers for their very careful and thorough assessment of our study. By performing additional analyses as well as altering the statements in our manuscript and discussing the limitations of our study in more depth we hope to meet the requirements of the reviewers.

The original western blots and images shown in the manuscript are provided in Supporting information, which is also stated in the Methods section. We now additionally provide a table containing all the raw data underlying the graphs and statistical analyses.

We used the PACE tool for converting our images to the required format.

Please find our responses to the individual remarks below. The lines indicating the changes refer to the manuscript with track changes.

Reviewer #1:

1) Why did the authors choose females and not males? Why use two months old animals rather than adult (3-6 months) mice? (3 months old mice were used for the GPR126 study)

Female mice were chosen for practical reasons: After the surgery, male mice are more prone to wound reopening than female mice, and they cannot be regrouped after a period of single housing to allow for wound healing. To avoid loss of animals in the experiment due to repeated wound reopening (which would require euthanasia according to our SOP) and to avoid prolonged single housing of animals, we performed the experiment with female mice only. These explanations have been integrated in the Methods section of the manuscript (lines 79-82 in the manuscript with track changes).

As to the age of the mice: the peripheral demyelinating disease developed by PrP knockout mice could interfere with remyelination, and we would not be able to distinguish this from an effect caused by the mere lack of PrP. To avoid confounding effects by impaired PrP-based myelin maintenance, we performed the experiments in mice at the youngest age possible (after completion of peripheral myelination). We included this explanation in the text (lines 199-203).

2) There are in general 3 animals/group; was this value of N chosen based on power analyses? If so, what were the effect sizes, variances, and desired power used in the analyses? This low value of N has implications for their conclusions. Some examples follow.

Sample sizes are similar to those of previous publications performing western blot, IF and EM analyses in sciatic nerve crush experiments [1–3]. Furthermore, they are in accordance with a sample size calculation based on the results from the CD68- and Iba1-immunohistochemistry studies reported in Mogha et al, J Neurosci, 2016 [1] (calculated with the G*power software version 3.1.9.7 with power 0.8, type I error rate of 5%, effect sizes ranging from 2-6 in [1]). Mogha et al. used an inducible knockout model. We expected less variability in our mouse model due to the complete knockout of PrP in contrast to the tamoxifen-induced Adgrg6 knockout in [1].

By performing the analyses at multiple time points and combining complementary methods, we aimed to further increase the validity of our conclusion. For the TEM studies, the acquisition and analysis of the whole sciatic nerve cross section provides a very precise and comprehensive readout, which increases the strength of our conclusion. In the extensive experience of our collaborator with nerve crush experiments, N = 3 is sufficient to detect clinically meaningful differences between groups – in particular when multiple time points are analysed [2,3].

We have adapted the respective section in Material and Methods accordingly and we included a discussion about the small sample size in lines 456-464.

3) It is clear that they failed to find differences in Figure 1, but the variance is sufficiently high that one would guess a substantially higher N would need to be sampled to detect differences smaller than a few-fold; this is also true for Figure 2b (KI67 data).

Please refer to the response above.

4) In Figure 3, the idea that macrophage recruitment peaked at 10 days postcrush cannot be supported by the data presented; it appears that days 10 and 16 are indistinguishable and may (or may not) be different from day 5 and day 30, but these statistical comparisons are not made.

We agree with the comment of the reviewer. Our data do not necessarily show that the number of macrophages peaks at 10 days post crush. We have altered the text accordingly. We did not perform additional comparisons since the exact peak of macrophage recruitment is not relevant for the conclusion that no difference can be detected between WT and PrP knockout mice. We have adapted the text accordingly (lines 315 and 333).

5) If the authors decide not to perform further experiments, they should perform power analyses and provide the results in the paper, so that the strength of their conclusions can be judged.

We have now provided the results of a power analysis based on Mogha et al, J Neurosci, 2016 [1] in the material and methods section. A post hoc power analysis of our own results does not provide any further insights [4]. We have added a paragraph to discuss the small sample size in the discussion (lines 456-464).

6) Minor note: I suggest plotting 95% confidence intervals rather than SEMs, which are not really meaningful for N=3.

We compared the graphs using CI or SEM for the error bars (see example in the attached "Response to Reviewers" Word document). When displayed in the figures, the shorter error bars representing the SEM (compared to the longer error bars for CI) enable a better discrimination of the individual points, which we are plotting for all experiments (except for the summary of the g-ratio). Therefore, we prefer to plot SEM in the figures. We argue that no relevant information is lost by plotting SEM instead of CI, 1) since we are plotting the individual data points and 2) the CI is directly related to SEM by t statistics. Furthermore, we are now providing all the raw data underlying the graphs in Supplementary Table S1. This will allow readers to reproduce and/or extend the statistical analysis.

7) Figure S2. The main purpose of providing whole blots for examination is to judge the degree to which one can be confident of antibody performance. This is quite difficult with the current figure. As one example, the calnexin blot shows a marked calnexin band near the bottom of the gel, even though this is a 90 kD protein. The entire gels should be shown, and the positions of all MW markers demarcated with arrows, rather than using an asterisk to denote the general area of the blot where the band of interest is said to migrate. Additionally, for reviewer purposes, these blots should be shown after incubation with a single primary antibody, not multiple antibodies. Finally, the methods used to validate the antibodies used are not described. A statement is made that the asterisks mark “specific” bands, but no justification is provided for the apparent assumption that bands migrating at different molecular weights from the asterisks are “non-specific” as opposed to specific but non-desired.

We have repeated the western blots without cutting the membranes. All molecular weight markers are now indicated on the images. We have performed stripping before subsequent incubations and described the procedure in the material and methods section. The unprocessed raw blots are provided in Supplementary Figure S2.

The antibodies were considered valid if a strong, consistent band was detected at the expected molecular weight. Additionally, the antibodies used in our study are commonly used in our laboratory for both western blotting and immunostaining. We have also used them in a previous study about the peripheral demyelination in Prnp knockout mice [5].

Missing study elements

8) The loss of GPR126/Adgrg6 function, specifically in Schwann cells, results in non-cell autonomous defects in axon regeneration and neuromuscular synapse formation. Clearly, axon regeneration is a sine qua non for peripheral nerve repair. However, neither axon regeneration nor NMJ reformation were examined in the current manuscript. Therefore, the statement that “PrP is dispensable for peripheral nerve repair” cannot be supported by the data provided. These experiments should be performed (ideally) or the conclusion statements should be modified.

We did not collect muscle tissue from the mice in our study. Thus, we unfortunately cannot perform an analysis of NMJ reformation without repeating the entire experiment, which we decided to be out of scope for the present study. We agree that NMJ reinnervation is an important part of peripheral nerve regeneration. We have altered our statements in the introduction and the discussion accordingly.

For axon regeneration, we now included a quantification of the total number of myelination-competent axons (i.e. diameter larger than 1um, in TEM) at 12 d.p.c and 30 d.p.c. as a rough measure of axon regeneration. The results are now included in lines 365-373 and Fig 5e. We also discuss axon regeneration in the limitations section of the discussion.

Reviewer #2: Major points

1.) previous results by the same group (e.g. Nuvolone et al 2016) are not sufficiently mentioned and discussed in the light of the new data

We have extended both the introduction and the discussion section to better represent the results of previous studies.

2.) the mouse model is not adequately introduced: I assume it is a constitutive mouse mutant with PrP deletion in all cell types? Where are deletion phenotypes expected? Neurons and/or Schwann cells? This has to be discussed carefully.

We have now better introduced the mouse model in the manuscript (lines 64 and 199-203).

3.) Data frequently rely on only single markers, e.g. c-Jun used for repair Schwann cells. Other markers should be used to confirm this result. Same is true for inflammation markers: here e.g. Iba1 and CD45 could also be used

For detection of repair Schwann cells, we used c-Jun and GFAP. Furthermore, quantification of early demyelination in TEM as well as Schwann cell proliferation can also be considered as indicators of functional repair Schwann cells. Thus, we consider our characterization of repair Schwann cells to be sufficient.

For recruitment of inflammatory cells, we have now performed additional immunofluorescent stainings at one of the time points (10 d.p.c.). The results are included in the manuscript (lines 318-320 and Figure 3d).

4.) The authors state that GFAP is used as a Schwann cell marker, a statement not referenced and not entirely true. Typically, it is used as marker for astrocytes.

While GFAP labels astrocytes (and, surprisingly, some cerebellar neuronal populations and some meningeal cells) in the central nervous system, it is also a reliable marker of repair Schwann cells in the peripheral nervous system. We now provide more background information to justify our choice of GFAP as a marker of repair Schwann cells (lines 249-252).

5.) The authors show altered GFAP expression between wt and mutant for the baseline. An alternative explanation to the one given by the authors might be that Prp suppresses neuroinflammation in wt mice. Please comment.

GFAP expression in PrP knockout mice is detectable at an age before infiltration by macrophages occurs and other morphological signs of demyelination can be detected [5,6]. We do interpret the increase in GFAP expression as an early sign of nerve damage occurring due to the absence of PrP. We currently do not know whether the damage is related to inflammatory processes. In our previous study [7], the demyelinating disease could not be suppressed in Rag-knockout mice, suggesting that B and T cells do not contribute to the pathogenesis.

6.) For the Ki67 no co-staining with cellular markers is provided, so it is unclear in which cell type cell proliferation occurs. Co-localization experiments should be performed.

We now performed a double staining with CD68, S100 and ki67 from nerves at 5 d.p.c. The results are now included in lines 270-275 and Figure 2c.

7.) For the CD68 marker ,authors previously (Nuvolone et al) described differences between wt and ko in baseline (Fig. 3b). Why is this not observed in the current study?

In Nuvolone et al, a significant difference in the presence of CD68 positive macrophages in the sciatic nerve was only observed at 9 months of age (and a trend towards increased macrophage numbers at 3 months of age). Thus, we do not expect a significant difference in the number of macrophages at 2 months of age. This also contributed to our decision of performing the crush experiments at 2 months of age. We aimed to avoid any interference with regeneration by increased numbers of macrophages in ZH3 mice at baseline. We now mention this in lines 199-200.

8.) The authors do not employ any functional assays to monitor nerve regeneration which limits their data interpretation. This limitation should be clearly stressed.

We have added a “limitations” section to the discussion (lines 441-464), where we discuss the lack of functional assays in our study.

9.) Results and quantification in Fig. 1e seem mainly to rely on unequal loading as depicted by calnexin. Please comment.

We agree with the reviewer that the loading control is uneven. Since we loaded the same amount of protein for all samples (10ug), we think that Calnexin is upregulated in sciatic nerves at 1-2 weeks post crush. We have now repeated the western blots with actin as loading control, and we also found a slight upregulation of actin at the investigated time points. To account for this, we are now presenting the protein levels as fold change to the average levels in crushed WT nerves.

10.) Numbers of animals at each timepoint are rather low (e.g. N=3). For instance in Fig. 2b there are 3 animals with one clear outlier. However, I see the point that authors include several timepoints. Nevertheless, low N-number should be discussed.

We agree that this is a limitation of our study. We are now discussing this point in the manuscript (please refer to the new “limitations” section of the discussion).

11.) No quantification for data in Fig. 2c is provided which should be included.

We have added the respective bar graph to Figure 2 and moved the descriptive statistics from the main text to the figure legend.

Minor points

1.) the introduction is overall very short and does not provide sufficient background

We have extended the introduction to introduce more background information.

2.) In the figures author should designate mutant mice with mutant rather than simply ZH3

We have changed the legends in all figures accordingly.

3.) Fig. 1b should also include uninjured even if values are zero

We have included the values in the graph.

References

[1] Mogha A, Harty BL, Carlin D, Joseph J, Sanchez NE, Suter U, et al. Gpr126/Adgrg6 Has Schwann Cell Autonomous and Nonautonomous Functions in Peripheral Nerve Injury and Repair. J Neurosci 2016;36:12351–67. https://doi.org/10.1523/JNEUROSCI.3854-15.2016.

[2] Gerber D, Ghidinelli M, Tinelli E, Somandin C, Gerber J, Pereira JA, et al. Schwann cells, but not Oligodendrocytes, Depend Strictly on Dynamin 2 Function. ELife 2019;8:e42404. https://doi.org/10.7554/eLife.42404.

[3] Norrmén C, Figlia G, Pfistner P, Pereira JA, Bachofner S, Suter U. mTORC1 Is Transiently Reactivated in Injured Nerves to Promote c-Jun Elevation and Schwann Cell Dedifferentiation. J Neurosci 2018;38:4811–28. https://doi.org/10.1523/JNEUROSCI.3619-17.2018.

[4] Zhang Y, Hedo R, Rivera A, Rull R, Richardson S, Tu XM. Post hoc power analysis: is it an informative and meaningful analysis? Gen Psych 2019;32:e100069. https://doi.org/10.1136/gpsych-2019-100069.

[5] Henzi A, Senatore A, Lakkaraju AKK, Scheckel C, Mühle J, Reimann R, et al. Soluble dimeric prion protein ligand activates Adgrg6 receptor but does not rescue early signs of demyelination in PrP-deficient mice. PLoS ONE 2020;15:e0242137. https://doi.org/10.1371/journal.pone.0242137.

[6] Nuvolone M, Hermann M, Sorce S, Russo G, Tiberi C, Schwarz P, et al. Strictly co-isogenic C57BL/6J-Prnp-/- mice: A rigorous resource for prion science. J Exp Med 2016;213:313–27. https://doi.org/10.1084/jem.20151610.

[7] Bremer J, Baumann F, Tiberi C, Wessig C, Fischer H, Schwarz P, et al. Axonal prion protein is required for peripheral myelin maintenance. Nat Neurosci 2010;13:310–8. https://doi.org/10.1038/nn.2483.

Decision Letter 1

Simone Di Giovanni

11 Jan 2021

The prion protein is not required for peripheral nerve de- and remyelination after crush injury

PONE-D-20-33989R1

Dear Dr. Aguzzi,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Simone Di Giovanni

Academic Editor

PLOS ONE

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: The authors have addressed most concerns adequately and added words of caution when interpreting data so I am happy to suggest accepting the manuscript

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Acceptance letter

Simone Di Giovanni

12 Jan 2021

PONE-D-20-33989R1

The prion protein is not required for peripheral nerve de- and remyelination after crush injury

Dear Dr. Aguzzi:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Simone Di Giovanni

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Nerve harvest after crush injury.

    The sciatic nerve was crushed using a forceps at the sciatic notch. For harvesting, the nerve was cut at 3 mm distal to the crush side. The proximal segment was embedded for electron microscopy (EM), the distal segment was used for immunofluorescence (IF) and western blotting.

    (TIFF)

    S2 Fig. Original western blot images.

    The uncropped blots have been inverted using the Affinity Photo software. Molecular weight markers used are indicated in kilo Dalton (kD). The arrows indicate the order in which the blots were incubated with primary antibodies. Stripping was performed before each incubation. The dashed line in blot Fig 1e indicates that the membrane was cut, and the upper and lower half were incubated with different antibodies.

    (TIF)

    S3 Fig. Original immunofluorescence images.

    The separate channels for each image are shown without alterations of contrast or brightness and no cropping.

    (TIF)

    S4 Fig. Original immunofluorescence images.

    The separate channels for each image are shown without alterations of contrast or brightness and no cropping.

    (TIF)

    S1 Table. Raw data used for graphs and calculations.

    (XLSX)

    Data Availability Statement

    All relevant data are within the paper and its Supporting information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES